Diabetes Fundamentals: Types, Diagnosis, Management, and Prevention

Diabetes Mellitus: A Comprehensive Overview

Diabetes is a group of metabolic disorders characterized by chronic hyperglycemia from defects in insulin secretion, insulin action, or both. It affects 38+ million Americans (11.6% of population); 1 in 5 undiagnosed.

Classification

TypePathophysiologyOnsetTreatment Core
Type 1 (T1D)Autoimmune β-cell destruction → absolute insulin deficiencyUsually <30 yrs (but any age)Insulin (basal-bolus or pump) — lifesaving
Type 2 (T2D)Insulin resistance + progressive β-cell failure → relative deficiencyUsually >40 yrs (increasing in youth)Lifestyle + metformin ± other agents ± insulin
Gestational (GDM)Placental hormones → insulin resistance in pregnancy24–28 wks gestationMedical nutrition therapy ± insulin/metformin
Other specific typesMODY, LADA, pancreatic, drug-induced, genetic syndromesVariableEtiology-directed

Diagnostic Criteria (ADA 2024)

TestNormalPrediabetesDiabetes
Fasting plasma glucose<100 mg/dL100–125≥126
HbA1c<5.7%5.7–6.4%≥6.5%
2-hr OGTT<140140–199≥200
Random PG + symptoms——≥200

Confirm with repeat testing unless classic hyperglycemia crisis.

Classic Symptoms (Hyperglycemia)

  • Polyuria, polydipsia, polyphagia
  • Unexplained weight loss (esp. T1D)
  • Fatigue, blurred vision
  • Recurrent infections (UTI, candidiasis), slow healing
  • Paresthesias (neuropathy)

Management Pillars

  1. Medical Nutrition Therapy: Individualized by RD; Mediterranean/DASH/plant-forward patterns; carb consistency/monitoring.
  2. Physical Activity: 150 min/week moderate aerobic + 2–3× resistance; reduce sedentary time.
  3. Pharmacotherapy: Metformin first-line T2D (unless contraindicated). Add agents per ASCVD/HF/CKD status, HbA1c, cost, preference (ADA/EASD algorithm).
  4. Glucose Monitoring: SMBG or CGM per regimen. T1D/insulin-using T2D → CGM standard.
  5. Cardiometabolic Risk Reduction: Statin, BP control (<130/80), SGLT2i/GLP-1 RA if ASCVD/HF/CKD, aspirin if indicated.
  6. Complication Screening: Annual dilated eye, UACR/eGFR, foot exam, lipid panel, dental.

Prevention (T2D Focus)

  • DPP lifestyle intervention: 7% weight loss + 150 min/week → 58% risk reduction (71% if >60 yrs).
  • Metformin for high-risk prediabetes (BMI ≥35, <60 yrs, GDM history).

Lifelong partnership: Diabetes requires a multidisciplinary team (PCP, endocrinologist, CDCES, RD, podiatrist, ophthalmologist, behavioral health) and an empowered patient. Regular follow-ups (q3–6 mo) adjust therapy to evolving life.

Diabetes - Related Articles